BioSpace News Archive

Thermo Fisher Scientific’s PPD Clinical Research Business Selected to Support National Cancer Institute’s Cancer Trials Support Unit.

Todos Medical, Ltd. reported the preprint in ResearchGate of a case study entitled “Consequences of Microclot Pathophysiology Underlying Long COVID Improved with Tollovid Supplementation.”

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today commented on the Centers for Medicare and Medicaid Services (“CMS”) development of new codes for the diagnosis and tracking of refractory angina.

Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the Brazilian National Agency of Supplementary Health (ANS) approved SIR-Spheres® Y-90 resin microspheres for the treatment of intermediate and advanced stage hepatocellular carcinoma (HCC) in Brazil.

A NEW targeted therapy to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia.

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug (RPD) designation for ABX1100, an investigational Centyrin-siRNA conjugate that targets the Gys1 gene in muscle, for the treatment of Pompe disease.